



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** July 4, 2008

**To:** Primary Clinical Research Associates

**From:** Janis Wobschall  
Research Protocol Specialist

**Re:** N0779, Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients with Recurrent Glioblastoma Multiforme

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note that this study was approved by the National Cancer Institute on March 13, 2008.

If you have any questions, please feel free to contact me.

Enclosure